Solution

Our technology uniquely combines biochemical and physical stimulation of immune cells.​

This innovative way of activating immune cells contributes to a significant enhancement of current therapeutic cell production steps, leading to shorter production time and better end product characteristics.

​immUni technology will enable to bringing these therapies one step closer to individuals in need.​

Cancer
Patient

+125%

Robust Activation

+90%

Optimized Gene Delivery

+120%

Faster Expansion

Patient
Treatment

about-us

About us

immUni technology has been born at ETH Zurich from more than a decade of committed research. With an interdisciplinary team that combines biophysics, immunology and nanotechnology, a novel platform has been invented that addresses critical unmet needs of the currently booming advanced cell therapeutics sector. Compared to standard technology this innovative solution achieves a differential immune cell activation, that allows for critical production time reduction and improved cell characteristics. ​

Our immUni team combines world leading science in mechano-immunology with entrepreneurial expertise in advanced cell therapies. Together with our established network of clinical collaborators we will be launching a first product applicable to CAR-T cell therapies research and development, as well as clinical production. ​

It is our mission to evolve our research from bench to bedside to improve patients’ lives towards a future where cell advanced therapies will become available to every citizen in need.

Technology

LEARN MORE ABOUT OUR SOLUTION

Disruptive technology contributing to advance adoptive therapies from bench to the bedside.

product-img-1

Science

After more than a decade of committed research, immUni was born from a unique interdisciplinary approach combining biophysics, immunology and nanotechnology.​

product-icon-1
product-img-1

Product

Our product is a unique combination of optimal biochemical and physical stimulation of immune cells. immUni first product will be available for immuno-oncology research and development. ​ ​

product-icon-1
product-img-1

Applications​

Our technology applied to CAR-T cell therapies enhances each step of the production process, resulting in very short production time and significant cost reduction, as well as improved therapeutic product. One step closer to the patient immUni will contribute to a novel point-of-care solution.

product-icon-1

Revolutionizing CAR-T cell therapy production

immUni disruptive technology overcomes major limitations of the traditional CAR-T cell production approaches, by achieving simultaneous reduction of production time and delivering a final CAR-T cell product with increased quality.​

  • cell-tharapy-1

    PROBLEM:

    Complex suboptimal production processes

  • cell-tharapy-1

    SOLUTION:​

    Differential cell activation, increased gene transfer efficiency, ​ reduced expansion time, enhanced final cells product

News

Follow Us On LinkedIn